期刊文献+

心脏原发轻链型淀粉样变1例报告并文献复习

Report of cardiac primary light-chain amyloidosis in one case and literature review
下载PDF
导出
摘要 目的探讨心脏原发轻链型淀粉样变临床特点、病理特征、诊断及治疗。方法报道1例心脏原发轻链型淀粉样并复习相关文献。结果心脏原发轻链型淀粉样变临床特点包括常见心力衰竭症状,顽固性低血压,心电图多有低电压,异常Q波等表现;超声心动图特异性表现为心内膜心肌呈现出闪耀的颗粒状;单克隆轻链异常增高;组织活检,经刚果红染色可见特异性淀粉样组织。常用治疗方法为MP或MD方案(美法仑+泼尼松或地塞米松)。结论心脏原发轻链型淀粉样变临床罕见,特异性临床表现少,组织活检、检测血清游离轻链为主要确诊手段;治疗为MP或MD方案。 Objective To discuss the clinical features, pathological characteristics, diagnosis, and treatment of cardiac primary light - chain amyloidosis. Methods A case of cardiac primary light - chain amyloidosis was reported, and relative literatures were reviewed. Results The main clinical features included heart failure, refractory hypotension, and low voltage and abnormal Q wave on the electrocardiogram, etc. The specificity of the ultrasonic cardiogram included the occurrence of particles in the cardiac muscle of endocardium and abnormal increase of monoclonal light chain. In the tissue biopsy, specific amyloidosis tissues could be observed after the staining by Congo red. The conventional treatment methods included MP or MD scheme (melphalan plus prednisone or dexamethasone ). Conclusion Cardiac primary light - chain amyloidosis is rarely seen in clinic, and there are few specific clinical manifestations. Tissue biopsy and serum free light chain detection are the main methods for the final diagnosis, and MP and MD schemes are the treatment methods.
出处 《西南国防医药》 CAS 2012年第10期1086-1089,共4页 Medical Journal of National Defending Forces in Southwest China
关键词 淀粉样变性 心脏 病例报告 amyloidosis heart case report
  • 相关文献

参考文献9

  • 1Falk R H, Comenzo R L, Skinner M. The systemic amyloidosis [J]. N Engl J Med, 1997, 337:898 - 909.
  • 2Kyle R A, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases [ J]. Semin Hematol, 1995, 32: 45 - 59.
  • 3赵新颜,贾继东,王宝恩,欧晓娟,钱林学,张福奎,王宇,崔焱.30例淀粉样变性患者的临床特点分析[J].中华肝脏病杂志,2005,13(1):42-44. 被引量:15
  • 4Cacoub P, Axler O, De Zuttere D. Amyloidosis and cardiac involvement[J]. Ann Med Interne, 2000, 151: 611.
  • 5Dispenzieril A, Kyler A, Gertz M A, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponinsIJ]. Lancet, 2003, 361:1787 - 1789.
  • 6Gertz M A, Comenzo R, Falk R H, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) : a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [ J ]. Am J Hematol,2005, 79 : 319 - 328.
  • 7张之南.血液病学[M].北京:人民卫生出版社,2003.1101-1106.
  • 8王学文.淀粉样变治疗学研究的最新进展[J].现代肿瘤医学,2011,19(1):172-176. 被引量:6
  • 9Gillmore J D, Goodman H J, Lachmann H J, et al. Sequential cardiac and autologous stem cell transplantation for systemic AL amyloidosis [ J ]. Blood, 2006, 107 : 1227 - 1229.

二级参考文献32

  • 1Leung N,Dispenzieri A,Fervenza FC,et al.Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis[J].Am J Kidney Dis,2005,46(2):270-277.
  • 2Jantunen E,Itala M,Lehtinen T,et al.Early treatment-related mortality in adult autologous stem cell transplant recipients:A nation-wide survey of 1482 transplanted patients[J].Eur J Haematol,2006,76 (3):245-250.
  • 3Cohen AD,Zhou P,Chou J,et al.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/-thalidomide for systemic light-chain amyloidosis:Results of a phase II trial[J].Br J Haematol,2007,139(2):224-233.
  • 4Wechalekar AD,Hawkins PN,Gillmore JD.Perspectives in treatment of AL amyloidosis[J].Br J Haematol,2007,140(2):365-377.
  • 5Palladini G,Merlini G.Current treatment of AL amyloidosis[J].Haematological,2009,94(8):1044-1048.
  • 6Jaccard A,Moreau P,Leblond V,et al.High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis[J].N Engl J Med,2007,357(11):1083-1093.
  • 7Lebovic D,Hoffman J,Levine BM,et al.Predictors of survival in patients with systemic lightchain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone[J].Br J Haematol,2008,143(3):369-373.
  • 8Palladini G,Russo P,Lavatelli F,et al.Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan,dexamethasone,and thalidomide[J].Ann Hematol,2009,88(2):347-350.
  • 9Gertz M,Lacy M,Dispenzieri A,et al.Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis[J].Leuk Lymphoma,2008,49(1):36-41.
  • 10Kumar S,Dispenzieri A,Lacy MQ,et al.Serum uric acid:novel prognostic factor in primary systemic amyloidosis[J].Mayo Clin Proc,2008,83(3):297-303.

共引文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部